Year: 2023

PALM SPRINGS, CA, Nov. 21, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Today, CuraScientific Corp, (the “Company”) (OTCPINK: CSTF) announces that the Company’s subsidiary, Cal Care Grp. Inc., will be opening its wholesale retail store in Palm Desert on December 1, 2023. William Reed, Chairman & CEO, stated, “Our cannabis division, Cal Care Grp, owns and operates JW Brands in the Palm Desert area of Southern California. Opening a cannabis wholesale retail store can be a lucrative business opportunity, but it also comes with various legal and operational considerations. Our team has projected $2M in 2024 revenue with the new wholesale store. We have established relationships with cannabis growers, cultivators, and manufacturers to secure a consistent and high-quality supply of products. We also have our own extraction...

Founder and CEO of DriveItAway Holdings, Inc. on Panel “Learning How to Optimize Super-Apps by Leveraging Relationships with Banks, External Vendors and Customers” PHILADELPHIA, Nov. 21, 2023 (GLOBE NEWSWIRE) — John F. Possumato, Founder and CEO of DriveItAway Holdings, Inc. (“DriveItAway”), (OTC Marketplace: DWAY), will be speaking at the annual FTT Embedded Finance & Super Apps Conference, where the most advanced disruptive community of retailers, manufacturers, insurers, telcos, financial institutions, fintech and tech innovators meet to present and discuss game changing advances in the interconnected world of embedded apps. Produced by VC Innovations, and held December 6-7, in San Francisco, California, this conference is collocated with the Customer Alpha and Future Identity Customer conferences, bringing together a group...

WATERTOWN, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) — Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, today announced the company’s president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat on Tuesday, November 28, 2023 at 8:30 a.m. ET at the Piper Sandler 35th Annual Healthcare Conference in New York, NY. To access the live webcast, visit the Events & Presentations page within the investor section of the company’s website at https://ir.acrivon.com/news-events/events-presentations....

CONSHOHOCKEN, Pa., Nov. 21, 2023 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Ronald Filippo has been appointed Chief Information Officer. Mr. Filippo has more than 25 years of digital experience in the biopharmaceutical industry and was previously Senior Vice President Digital at Moderna, where he was responsible for technology leadership and digital transformation across core operations during the commercialization of the company’s COVID-19 vaccine. Bill Sibold, Chief Executive Officer of Madrigal, stated, “Ron’s skillset and depth of digital experience will be a tremendous asset for Madrigal as we prepare for a first-to-market launch of resmetirom. His appointment reflects our...

The presentation will detail the latest promising research discoveries in Coretec’s CSpace 3D display technology ANN ARBOR, Mich., Nov. 21, 2023 (GLOBE NEWSWIRE) — The Coretec Group (OTCQB: CRTG), developers of silicon anode active materials for lithium-ion batteries, and cyclohexasilane (CHS) for EV, cleantech, and 3D display technology, today announced that its research in partnership with The University of Adelaide on its CSpace 3D volumetric display technology has been selected for presentation at the 2024 SPIE Photonics West Conference. Taking place in San Francisco, CA, on January 30, 2024 at 4:40 pm PST, the presentation details the most recent CSpace research developments. It will be given by Adelaide’s Dr. Yunle Wei. The presentation is based on Coretec’s CSpace technology that utilizes two invisible infrared lasers to...

WATERTOWN, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) — Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, announced that the company approved a grant of equity award under its 2023 Inducement Plan to one employee. The equity award was granted in the form of stock options and has a grant date of November 17, 2023. The employee received options to purchase 57,900 shares of Acrivon common stock. The stock options will vest 25% on the first anniversary of the first day of the month following the...

RENO, Nev., Nov. 21, 2023 (GLOBE NEWSWIRE) — Aqua Metals, Inc. (NASDAQ: AQMS) (“Aqua Metals” or the “Company”), a pioneer in sustainable lithium battery recycling, today announced that Steve Cotton, President & Chief Executive Officer, and Judd Merrill, Chief Financial Officer, will participate in the following investor conferences during December 2023.Janney Montgomery Scott Clean Energy Investment Symposium, December 6, 2023, New Orleans: Mr. Cotton and Mr. Merrill will conduct in-person, one-on-one meetings with investors. To register for the conference and schedule a meeting with management, please visit https://www.meetmax.com/sched/event_94999/conference_register.html. The Benchmark Company Discovery Conference, December 7, 2023, New York: Mr. Cotton and Mr. Merrill will conduct in-person, one-on-one meetings with...

MOUNTAIN VIEW, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) — NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced will present at the Piper Sandler 35th Annual Healthcare Conference, taking place November 28-30 in New York, NY. Joel Becker, NeuroPace’s Chief Executive Officer, will provide a corporate presentation on Tuesday, November 28 at 2:30pm ET, and management will participate in one-on-one meetings with investors during the conference. The presentation will be accessible via a live webcast here. A webcast replay of the presentation will be available on the Events section of NeuroPace’s Investor website at https://investors.neuropace.com/news-and-events/events. About NeuroPace, Inc. Based in Mountain View, Calif., NeuroPace...

Fobi continues to drive momentum in the sports and entertainment industry, signing multiple new deals with hockey organizations across North America. VANCOUVER, BC, Nov. 21, 2023 (GLOBE NEWSWIRE) — Fobi AI Inc. (FOBI:TSXV) (FOBIF:OTCQB) (the “Company” or “Fobi”), an industry leader in harnessing AI and data intelligence to enable digital transformation, is pleased to announce that the Company’s wallet pass technology has been formally implemented with several ice hockey organizations across North America, including the American Hockey League (AHL) and the Ontario Hockey League (OHL). Through its wallet pass platform, Passcreator, Fobi’s digital credential solution provides various hockey teams with a secure and convenient digital alternative to traditional identification cards. Fobi’s demonstrated...

NX-13, a Novel, Oral, NLRX1 Agonist, was Observed to be Well Tolerated and Demonstrated Early Signs of Rapid Symptomatic Relief and Endoscopic Improvement in Patients with Ulcerative Colitis NEXUS Phase 2 Proof-of-Concept Study is Ongoing, with Top-Line Readout Expected in Q4 2024 NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) — Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced a peer-reviewed publication describing the safety, tolerability, pharmacokinetic and clinical efficacy results for the NX-13 Phase 1b trial in patients with ulcerative colitis (UC) in the Journal of Crohn’s and Colitis. “We are delighted to have our Phase 1b results of NX-13 in UC published in the Journal of Crohn’s and Colitis,” said Dr. Fabio...